Acumen Pharmaceuticals, Inc. (ABOS)

Acumen Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	-	-	-	-	1.44
Revenue Growth (YoY)	-	-	-	-	-15.38%
Cost of Revenue	93.8	42.32	32.36	12.31	8
Gross Profit	-93.8	-42.32	-32.36	-12.31	-6.56
Selling, General & Admin	20.22	18.82	12.88	7.28	1.35
Operating Expenses	20.22	18.82	12.88	7.28	1.35
Operating Income	-114.02	-61.14	-45.24	-19.58	-7.91
Interest Expense	-4.07	-0.58	-	-	-
Interest & Investment Income	14.32	10.79	2.39	0.24	0
Other Non Operating Income (Expenses)	1.44	-1.44	-0.01	-81.11	0.59
EBT Excluding Unusual Items	-102.33	-52.37	-42.86	-100.45	-7.33
Gain (Loss) on Sale of Investments	-	-	-	-0.16	-
Pretax Income	-102.33	-52.37	-42.86	-100.61	-7.33
Net Income	-102.33	-52.37	-42.86	-100.61	-7.33
Net Income to Common	-102.33	-52.37	-42.86	-100.61	-7.33
Shares Outstanding (Basic)	60	49	41	20	0
Shares Outstanding (Diluted)	60	49	41	20	0
Shares Change (YoY)	23.46%	19.72%	102.43%	4685.59%	-2.73%
EPS (Basic)	-1.71	-1.08	-1.06	-5.02	-17.48
EPS (Diluted)	-1.71	-1.08	-1.06	-5.02	-17.48
Free Cash Flow	-86.23	-43.09	-35.31	-18	-7.45
Free Cash Flow Per Share	-1.44	-0.89	-0.87	-0.90	-17.77
Operating Margin	-	-	-	-	-550.98%
Profit Margin	-	-	-	-	-510.10%
Free Cash Flow Margin	-	-	-	-	-518.80%
EBITDA	-113.95	-61.08	-45.21	-19.58	-
D&A For EBITDA	0.06	0.06	0.03	0	-
EBIT	-114.02	-61.14	-45.24	-19.58	-7.91

Updated Mar 27, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q